Navigation Links
Favrille Announces Receipt of Nasdaq Letters
Date:7/15/2008

SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL) today announced that it has received Nasdaq staff deficiency letters dated July 9, 2008 indicating that, for the last 30 consecutive trading days, (i) the closing bid price for Favrille's common stock has been below the minimum $1.00 per share requirement and (ii) Favrille has not maintained the $5,000,000 minimum market value of publicly held shares as required for continued inclusion on the Nasdaq Global Market under Marketplace Rules 4450(a)(5) and (2), respectively. In accordance with Marketplace Rule 4450(e)(1), Favrille has 90 calendar days, or until October 7, 2008, to regain compliance with the $5,000,000 minimum market value requirement. In accordance with Marketplace Rule 4450(e)(2), Favrille has 180 calendar days, or until January 5, 2009, to regain compliance with the minimum $1.00 per share requirement. If Favrille does not regain compliance with either of the above Marketplace Rules within the applicable required timeframes, Nasdaq will provide written notification that Favrille's common stock will be delisted, after which Favrille may appeal the staff determination to the Nasdaq Listing Qualifications Panel if it so chooses.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward- looking statements involve known and unknown risks, uncertainties and oth
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. Favrille CEO to Present at Bear Stearns Healthcare Conference
3. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
4. Favrille to Present at BIO InvestorForum
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille Announces $21.1 Million Registered Direct Offering
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Mo. From cell phones to cars and ... life. Scientists and technology companies constantly are seeking ... for the first time using a water-based solution, ... a long-lasting and more efficient nuclear battery that ... a reliable energy source in automobiles and also ...
(Date:9/16/2014)... BlueInGreen® , a water quality company ... dissolved gases into liquids, announced the addition of ... representative firm to its sales network. H2Flow will ... and wastewater applications in the Canadian provinces of ... 1992 and serves Quebec and Ontario markets for ...
(Date:9/16/2014)... Fresne, President and CEO of Egenix, Inc. is pleased to ... its Scientific Advisory Committee. Dr. Vagner, a graduate ... performed research at Embl (European Molecular Biology Laboratory) Heidelberg, ... of health and medical research. He is a Research Director ... France , and at the Gustave Roussy ...
(Date:9/16/2014)... 16, 2014  The Council for Entrepreneurial Development ... in the country, today released a mid-year update ... It showed that in the first ... startups in the technology, life science, advanced ... from a variety of sources. Significant investment in technology ...
Breaking Biology Technology:BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... Oct. 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on endocrine therapy and ... intended to complete the clinical development of the ... macimorelin (AEZS-130) which could be the first oral ...
... Calif., Oct. 18 /PRNewswire / -- ... of human induced pluripotent stem cells (iPSCs) using a ... and efficiency of reprogramming. The discoveries, which were ... between Fate Therapeutics and The Scripps Research Institute (TSRI), ...
... Oct. 16 Summerhill Biomass Systems is planting the seeds ... named after the Cayuga County community where the technology was ... for grinding up timber, brush, corn stalks and other plant ... James T. McKnight, Summerhill president and co-founder, said he,s eager ...
Cached Biology Technology:AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 2Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 3Summerhill Biomass Systems Unveils Solid Biomass Technology System at Syracuse Expo 2Summerhill Biomass Systems Unveils Solid Biomass Technology System at Syracuse Expo 3
(Date:9/16/2014)... -- Valencell, Inc., a leader in performance biometric data sensor ... Companies" representing North Carolina,s hottest ... Conference on September 16-17 th at the ... Raleigh, North Carolina . Valencell,s President Dr. ... "Digital Health Spotlight Sector" on how the Company,s internationally ...
(Date:9/16/2014)... , Sept. 16, 2014 As open enrollment ... important decisions about their 2015 benefits. According to ... solutions business of Aon plc (NYSE: ... a more proactive role in managing their health care ... ever for individuals to understand how they can make ...
(Date:9/15/2014)... and gut microbes influence processes from digestion to disease ... most biodiverse terrestrial ecosystems on the planet, more is ... the tropics. Smithsonian scientists and colleagues working on Panama,s ... a single tree were home to more than 400 ... tree species contained more than 7,000 different kinds. , ...
Breaking Biology News(10 mins):Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7Smithsonian scientists discover tropical tree microbiome in Panama 2
... published today in Biology Letters found that ship ... found little evidence that crabs acclimatise to noise over time. ... found that crabs exposed to recordings of ship noise showed ... real world this could have implications for growth and, if ...
... demographics likely put you at risk for salt-sensitive hypertension, ... you. The concept is that free radicals in ... rather than eliminate excess through urination. Excess sodium, in ... hypertension researcher in the Section of Experimental Medicine at ...
... March 2013 issue of The Journal of Urology , ... study conducted by four physicians from Radiotherapy Clinics of ... study, 25 Year Disease Free Survival Rate after Irradiation ... of Recurrence Used for Radical Prostatectomy, is the first-ever ...
Cached Biology News:Ship noise makes crabs get crabby 2Sodium transporter appears likely target for treating salt-sensitive hypertension 2Georgia Physicians' Study Published in The Journal of Urology 2Georgia Physicians' Study Published in The Journal of Urology 3Georgia Physicians' Study Published in The Journal of Urology 4
...
... new Class II safety cabinets Heraeus HERAsafe KS ... user-orientated design. ,The new frameless slanted window ... area. The new front window design makes it ... large work aperture with a height of more ...
... has recently launched a custom synthesis ... (siRNA). Thermos siRNA molecules are: ... 2 DNA bases overhang at the ... Delivered fully deprotected and ready-to-use. ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
Biology Products: